Non-profit group's support helps Repligen win Pfizer deal for SMA drug
This article was originally published in Scrip
Repligen has made progress in its recent shift away from drug development to focus on bioprocessing by licensing its Phase I spinal muscular atrophy (SMA) program to Pfizer for up to $70 million plus royalties, in a deal that validates the more than $13 million invested by the non-profit group Families of SMA (FSMA) in the small molecule enzyme inhibitor RG3039.
You may also be interested in...
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.